Moreover, deregulation of key signaling pathways—including PI3K–AKT, RB–E2F, and MEK—as well as abnormal PD-L1 expression, are frequently observed in metastatic tumors and are associated with resistance to ICIs. Here, AKT1 is linked to metastatic neoplasm.